Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

HIV: Shock and kill.

Deeks SG.

Nature. 2012 Jul 25;487(7408):439-40. doi: 10.1038/487439a. No abstract available.

PMID:
22836995
2.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM.

Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.

3.

Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals.

Ho YC, Laird GM, Siliciano RF.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):6860-1. doi: 10.1073/pnas.1405194111. Epub 2014 May 5. No abstract available.

4.

[HIV eradication--facts and fiction].

Jaeger H, Wolf E.

MMW Fortschr Med. 2008 Apr 28;150 Spec No 1:72-3. German. No abstract available.

PMID:
19024923
5.

HDAC inhibitors in HIV.

Wightman F, Ellenberg P, Churchill M, Lewin SR.

Immunol Cell Biol. 2012 Jan;90(1):47-54. doi: 10.1038/icb.2011.95. Epub 2011 Nov 15. Review.

PMID:
22083528
6.

[Alarm clock for dormant HI viruses].

[No authors listed]

MMW Fortschr Med. 2014 Oct 9;156(17):32. German. No abstract available.

PMID:
25417463
7.

Current views on HIV-1 latency, persistence, and cure.

Melkova Z, Shankaran P, Madlenakova M, Bodor J.

Folia Microbiol (Praha). 2017 Jan;62(1):73-87. doi: 10.1007/s12223-016-0474-7. Epub 2016 Oct 5. Review.

PMID:
27709447
8.
9.

Latency reversal and viral clearance to cure HIV-1.

Margolis DM, Garcia JV, Hazuda DJ, Haynes BF.

Science. 2016 Jul 22;353(6297):aaf6517. doi: 10.1126/science.aaf6517. Review.

10.

The development of immune-modulating compounds to disrupt HIV latency.

Remoli AL, Marsili G, Battistini A, Sgarbanti M.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):159-72. doi: 10.1016/j.cytogfr.2012.05.003. Epub 2012 Jul 4. Review.

PMID:
22766356
11.

Therapeutics for HIV-1 reactivation from latency.

Sgarbanti M, Battistini A.

Curr Opin Virol. 2013 Aug;3(4):394-401. doi: 10.1016/j.coviro.2013.06.001. Epub 2013 Jun 28. Review.

PMID:
23810462
12.

HIV cure: knocking on the door.

Durand CM, Flexner C.

Clin Pharmacol Ther. 2013 May;93(5):382-4. doi: 10.1038/clpt.2013.22.

PMID:
23598454
13.

Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.

Sluis-Cremer N.

Curr Top Med Chem. 2016;16(10):1191-7. Review.

PMID:
26324046
14.

HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.

Battistini A, Sgarbanti M.

Viruses. 2014 Apr 14;6(4):1715-58. doi: 10.3390/v6041715. Review.

15.

Reversal of Latency as Part of a Cure for HIV-1.

Rasmussen TA, Tolstrup M, S√łgaard OS.

Trends Microbiol. 2016 Feb;24(2):90-7. doi: 10.1016/j.tim.2015.11.003. Epub 2015 Dec 11. Review.

PMID:
26690612
16.

As good as it gets? The problem of HIV persistence despite antiretroviral drugs.

Sigal A, Baltimore D.

Cell Host Microbe. 2012 Aug 16;12(2):132-8. doi: 10.1016/j.chom.2012.07.005.

17.

Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.

Euler Z, Alter G.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):13-24. doi: 10.1089/AID.2014.0235.

18.

Silent, but deadly--eliminating reservoirs of latent HIV.

Kay MS.

Trends Biotechnol. 2003 Oct;21(10):420-3. No abstract available.

PMID:
14512225
19.

New drugs for HIV-1: challenges and novel candidates.

Ward CJ.

Expert Rev Anti Infect Ther. 2010 Oct;8(10):1093-5. doi: 10.1586/eri.10.101.

PMID:
20954873
20.

The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.

Lucera MB, Tilton CA, Mao H, Dobrowolski C, Tabler CO, Haqqani AA, Karn J, Tilton JC.

J Virol. 2014 Sep;88(18):10803-12. doi: 10.1128/JVI.00320-14. Epub 2014 Jul 9.

Supplemental Content

Support Center